Marc Chioda

624 total citations
14 papers, 276 citations indexed

About

Marc Chioda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Marc Chioda has authored 14 papers receiving a total of 276 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Marc Chioda's work include Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Genomics and Diagnostics (3 papers). Marc Chioda is often cited by papers focused on Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Genomics and Diagnostics (3 papers). Marc Chioda collaborates with scholars based in United States, Australia and United Kingdom. Marc Chioda's co-authors include Gerson Peltz, Holger Thurm, Enriqueta Felip, Todd M. Bauer, Alice T. Shaw, Benjamin Solomon, Geeta Devgan, Lindsey Parker, Elizabeth T. Masters and Craig H. Reynolds and has published in prestigious journals such as Journal of Clinical Oncology, Tetrahedron Letters and Molecular Cancer Therapeutics.

In The Last Decade

Marc Chioda

14 papers receiving 271 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc Chioda United States	9	185	181	77	42	25	14	276
Evan Rogers United States	8	188 1.0×	154 0.9×	142 1.8×	52 1.2×	27 1.1×	25	267
Guilherme Harada Brazil	11	161 0.9×	155 0.9×	90 1.2×	66 1.6×	32 1.3×	40	317
Masayuki Yasugi Japan	9	241 1.3×	240 1.3×	132 1.7×	48 1.1×	38 1.5×	22	358
L. Paz-Ares Spain	9	215 1.2×	291 1.6×	97 1.3×	40 1.0×	38 1.5×	51	374
Mariona Riudavets Spain	9	197 1.1×	269 1.5×	74 1.0×	40 1.0×	13 0.5×	28	433
Olen Stephens New Zealand	5	118 0.6×	132 0.7×	80 1.0×	46 1.1×	30 1.2×	7	243
Erica Quaquarini Italy	11	155 0.8×	230 1.3×	81 1.1×	90 2.1×	32 1.3×	32	376
C. Massard France	11	130 0.7×	87 0.5×	141 1.8×	55 1.3×	21 0.8×	40	325
Masayoshi Miyawaki Japan	5	226 1.2×	180 1.0×	121 1.6×	44 1.0×	23 0.9×	7	261
Kimberly Harrow United States	6	204 1.1×	177 1.0×	104 1.4×	31 0.7×	15 0.6×	26	234

Countries citing papers authored by Marc Chioda

Since Specialization

Citations

This map shows the geographic impact of Marc Chioda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Chioda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Chioda more than expected).

Fields of papers citing papers by Marc Chioda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Chioda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Chioda. The network helps show where Marc Chioda may publish in the future.

Co-authorship network of co-authors of Marc Chioda

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Chioda. A scholar is included among the top collaborators of Marc Chioda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Chioda. Marc Chioda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Epstein, Robert S., et al.. (2022). Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER‐medicare study. Cancer Treatment and Research Communications. 31. 100555–100555. 7 indexed citations

Abraham, Ivo, Amit Goyal, Baris Deniz, et al.. (2022). Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States. Journal of Managed Care & Specialty Pharmacy. 28(4). 435–448. 7 indexed citations

Scott, J., et al.. (2022). HSR22-167: Burden of Myelosuppression Among Patients With Extensive-Stage Small Cell Lung Cancer Treated With Chemotherapy in a Community Oncology Setting. Journal of the National Comprehensive Cancer Network. 20(3.5). HSR22–167. 1 indexed citations

Abraham, Ivo, et al.. (2021). Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy. Journal of Medical Economics. 24(sup1). 71–83. 11 indexed citations

Waterhouse, David, Janet L. Espirito, Marc Chioda, et al.. (2020). Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer. Drugs - Real World Outcomes. 7(4). 261–269. 14 indexed citations

Chioda, Marc, et al.. (2020). Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners. Advances in Therapy. 37(6). 3019–3030. 36 indexed citations

Goldsmith, Kelly C., Susan Groshen, Marc Chioda, et al.. (2020). Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.. Journal of Clinical Oncology. 38(15_suppl). 10504–10504. 20 indexed citations

Copley‐Merriman, Catherine, James A. Kaye, Marc Chioda, et al.. (2019). <p>Systematic review of sequencing of ALK inhibitors in <em>ALK</em>-positive non-small-cell lung cancer</p>. PubMed. Volume 10. 11–20. 16 indexed citations

Bauer, Todd M., Enriqueta Felip, Benjamin Solomon, et al.. (2019). Clinical Management of Adverse Events Associated with Lorlatinib. The Oncologist. 24(8). 1103–1110. 112 indexed citations

10.

Reynolds, Craig H., Elizabeth T. Masters, Marley Boyd, et al.. (2018). Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study. Journal of Clinical Medicine. 7(6). 129–129. 9 indexed citations

11.

Reynolds, Craig H., Elizabeth T. Masters, Jack Mardekian, et al.. (2017). P3.02a-019 Real World Utilization and Outcomes of ALK-Positive Crizotinib Treated Metastatic NSCLC Patients in US Community Oncology Practice. Journal of Thoracic Oncology. 12(1). S1172–S1173. 1 indexed citations

12.

Levy, Benjamin, Marc Chioda, John Longshore, et al.. (2015). Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. The Oncologist. 20(10). 1175–1181. 25 indexed citations

13.

Schwab, Phil, et al.. (2015). Abstract B102: NSCLC observations combining medical charts and administrative claims data. Molecular Cancer Therapeutics. 14(12_Supplement_2). B102–B102. 1 indexed citations

14.

Chobanian, Harry R., Ping Liu, Marc Chioda, Yan Guo, & Linus S. Lin. (2007). A facile, microwave-assisted, palladium-catalyzed arylation of acetone. Tetrahedron Letters. 48(7). 1213–1216. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact